This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Live coverage has ended. The full story is below.
UnitedHealth Group (NYSE: UNH | UNH Price Prediction) posted mixed second-quarter results, as topline revenue of $111.6B beat expectations, but adjusted EPS of $4.08 sharply missed analyst estimates of $5.99. The company’s performance was dragged down by a $1.2B charge tied to its individual exchange business and other discrete items. Despite the earnings miss, UNH reinstated full-year guidance and struck a constructive tone on its long-term recovery path.
So far in pre-market trading, the stock is down 2.18% as of 8:30 AM EDT.
| Metric |
Estimate |
Actual |
Result |
| Revenue |
$111.59B |
$111.62B |
✅ Beat |
| Adj. EPS |
$5.99 |
$4.08 |
❌ Miss |
| Net Margin |
– |
3.1% |
❌ Miss YoY (4.3%) |
| Medical Cost Ratio |
– |
89.4% |
❌ Unfavorable YoY (+430 bps) |
Guidance Update: UNH Reinstates Full-Year Outlook
After suspending its 2025 forecast in May due to volatility in medical trends, UNH has reinstated its full-year guidance:
-
FY25 Adjusted EPS: At least $16.00
-
FY25 Revenue: $445.5B–$448.0B
-
Medical Cost Ratio: 89.25% ± 25 bps
-
Operating Margin: 4.8%–5.0%
This implies a more stable second half, even though pricing still lags the cost trend in key segments.
We’ve embarked on a rigorous path back to being a high-performing company fully serving the health needs of individuals and society… guided by a culture of service and longstanding values
CEO Stephen Hemsley emphasized a shift toward cost discipline and long-term structural improvements:
Contact [email protected] for any questions or corrections.